Skip to main content

Table 3 Antimicrobial activity against respiratory Pseudomonas aeruginosa isolates by region (ATLAS 2016–2018)

From: In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016–2018)

Region

Antimicrobial

MIC (mg/L)

%S + %Ia

%R

MIC90

Range

Africa/Middle East

(n = 471)

Piperacillin-tazobactam

128

0.25–≥256

73.5

26.5

Aztreonam

32

0.06–≥256

79.8

20.2

Ceftazidime

64

0.12–≥256

79.0

21.0

Ceftazidime-avibactam

8

≤0.015–≥256

91.9

8.1

Cefepime

32

≤0.12–≥64

76.6

23.4

Imipenem

≥16

0.06–≥16

66.7

33.3

Meropenemb

16

0.015–≥32

82.8

17.2

Levofloxacin

≥16

0.03–≥16

65.2

34.8

Colistin

2

0.12–4

99.8

0.2

Amikacin

16

≤0.25–≥128

92.1

7.9

Asia/South Pacific

(n = 1007)

Piperacillin-tazobactam

128

≤0.12–≥256

72.7

27.3

Aztreonam

32

≤0.015–≥256

79.5

20.5

Ceftazidime

64

0.06–≥256

76.3

23.7

Ceftazidime-avibactam

8

≤0.015–≥256

93.4

6.6

Cefepime

32

≤0.12–≥64

79.3

20.7

Imipenem

≥16

0.12–≥16

80.1

19.9

Meropenemb

8

0.008–≥32

90.1

9.9

Levofloxacin

≥16

0.008–≥16

66.7

33.3

Colistin

2

≤0.06–≥16

99.2

0.8

Amikacin

8

≤0.25–≥128

95.6

4.4

Europe

(n = 3049)

Piperacillin-tazobactam

128

≤0.12–≥256

69.2

30.8

Aztreonam

32

0.03–≥256

76.5

23.5

Ceftazidime

64

0.06–≥256

74.0

26.0

Ceftazidime-avibactam

8

≤0.015–≥256

91.0

9.0

Cefepime

32

≤0.12–≥64

76.0

24.0

Imipenem

≥16

≤0.03–≥16

69.3

30.7

Meropenemb

16

0.008–≥32

83.1

16.9

Levofloxacin

≥16

0.015–≥16

59.9

40.1

Colistin

1

≤0.06–≥16

99.7

0.3

Amikacin

32

≤0.25–≥128

89.8

10.2

Latin America

(n = 805)

Piperacillin-tazobactam

128

0.25–≥256

69.3

30.7

Aztreonam

64

0.06–≥256

75.9

24.1

Ceftazidime

128

0.06–≥256

71.2

28.8

Ceftazidime-avibactam

32

0.03–≥256

85.7

14.3

Cefepime

32

≤0.12–≥64

72.3

27.7

Imipenem

≥16

0.12–≥16

62.6

37.4

Meropenemb

16

≤0.004–≥32

76.6

23.4

Levofloxacin

≥16

0.015–≥16

60.7

39.3

Colistin

1

≤0.06–≥16

99.5

0.5

Amikacin

64

≤0.25–≥128

82.4

17.6

  1. MIC minimum inhibitory concentration; MIC90 MIC required to inhibit the growth of 90% of isolates; %S percent susceptible, standard dosing regimen; %I percent susceptible, increased exposure; %R percent resistant
  2. aIncludes all isolates not in the resistant category for all antimicrobial agents
  3. bThe breakdown of meropenem %S and %I data is: Africa/Middle East, 67.5% (%S) and 15.3% (%I); Asia/South Pacific, 79.7% (%S) and 10.3% (%I); Europe, 69.5% (%S) and 13.6% (%I); Latin America, 63.0% (%S) and 13.7% (%I)